Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Amyloid » Anti -APP (Amyloid beta A4 Protein, ABPP, APPI, Alzheimer Disease Amyloid Protein, Cerebral Vascular Amyloid Peptide, CVAP, PreA4, Protease Nexin-II, PN-II, A4, AD1)

Anti -APP (Amyloid beta A4 Protein, ABPP, APPI, Alzheimer Disease Amyloid Protein,
Cerebral Vascular Amyloid Peptide, CVAP, PreA4, Protease Nexin-II, PN-II, A4, AD1)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Monoclonal Mouse Purified E B IH
Amyloid-beta precursor protein (APP) is the source of the amyloid-beta (Ab) peptide found in neuritic plaques of Alzheimer's disease (AD) patients. APP is aglycosylated transmembrane protein with a long extracellular N-terminal domain, a short intracellular C-terminal domain, and an Abeta-segment of intermediate length shared between the intra- and extracellular regions. APP is cleaved by alpha-secretase immediately before or after reaching the cell surface, releasing the nonamyloidogenic secreted form of the N-terminal soluble APP fragment (sAPPa). APP molecules that are not cleaved by alpha-secretase are internalized, and subjected to beta-site cleavage by beta-secretase, leaving behind a membrane-bound C-terminal stub. This terminal stub is the substrate for gamma-secretase, which cleaves the molecule at gamma-site(s) to release the 40aa, 42aa, or 43aa-long Ab peptides. Processing of APP by beta and gamma-secretases occurs under normal physiological conditions, indicating that all fragments of APP, including Ab, play roles in normal physiology. In neurons, around 95% of APP is cleaved by gamma-secretases while 5% is cleaved by beta-secretase. Excessive generation of Ab and its subsequent oligomerization and fibrillation leads to the detrimental effects of AD. Reductions in the level or activity of certain APP fragments, in addition to accumulation of Ab, may play a critical role in the cognitive dysfunction associated aith AD, especially in the early stages of the disease. APP fragments including Ab regulate key neural functions including cell excitability, synaptic transmission, long-term potentiation, behavorial learning, and memory.
Catalog #A2275-84G
ApplicationsSuitable for use in ELISA, Western Blot and Immunohistochemistry.Other applications not tested.
Recommended DilutionWestern Blot: 1:500-1:1000
Immunohistochemistry (Formalin-fixed, paraffin-embedded): 2.5ug/ml
Optimal dilutions to be determined by the researcher.
Storage and StabilityMay be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Clone TypeMonoclonal
IsotypeIgG2b,k
Clone NoJ4H9
HostMouse
SourceHuman
Concentration~1mg/ml
FormSupplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
PurityPurified
ImmunogenRecombinant corresponding to aa18-289 human APP, expressed in E. coli.
SpecificityRecognizes human APP.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links